dc.date.accessioned | 2023-02-10T18:37:22Z | |
dc.date.available | 2023-12-14T23:46:20Z | |
dc.date.created | 2023-01-27T14:16:41Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Cortese, Rosa Battagili, Marco Prados, Ferran Boanchi, Alessia Haider, Lukas Jacob, Anu Palace, Jacqueline Messina, Silvia Paul, Friedemann Wuerfel, Jens Marignier, Romain Durand-Dubief, Francoise Rimkus, Carolina de Medeiros Callegaro, Dagoberto Sato, Douglas K Filippi, Massimo Rocca, Maria A. Cacciaguerra, Laura Rovira, Alex Sastre-Garriga, Jaume Arrambide, Georgina Liu, Yaou Duan, Yunyun Gasperini, Claudio Tortorella, Carla Ruggieri, Serena Maria Pia, Amato Ulivelli, Monica Groppa, Sergiu Grothe, Matthias Llufriu, Sara Sepulveda, Maria Lukas, Carsten Bellenberg, Barbara Schneider, Ruth Sowa, Piotr Celius, Elisabeth Gulowsen Proebstel, Anne-Katrin Yaldizli, Özgür Müller, Jannis Stankoff, B Bodini, Benedetta Carmisciano, Luca Sormani, Maria Pia Barkhof, Frederik Stefano, Nicola De Ciccarelli, Olga . Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. 2022 | |
dc.identifier.uri | http://hdl.handle.net/10852/99895 | |
dc.description.abstract | Abstract
MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG-antibodies is unavailable or shows uncertain results.
We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of MOG-antibody disease patients in clinical practice.
In this cross-sectional retrospective study, data from 16 MAGNIMS centres were included. Data collection and analyses were conducted from 2019 to 2021. Inclusion criteria were: diagnosis of MOG-antibody disease, AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis, brain and cord MRI at least 6 months from relapse, EDSS on the day of MRI. Brain white matter T2 lesions, T1-hypointense lesions, cortical and cord lesions were identified. Random-forest models were constructed to classify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosis; a leave one out cross-validation procedure assessed the performance of the models. Based on the best discriminators between diseases, we proposed a guide to target investigations for MOG-antibody disease.
One hundred sixty-two patients with MOG-antibody disease (99F, mean age: 41 [±14] years, median EDSS: 2 [0-7.5]), 162 with AQP4-neuromyelitis optica spectrum disorder (132F, mean age: 51 [±14] years, median EDSS: 3.5 [0-8]), 189 with multiple sclerosis (132F, mean age: 40 [±10] years, median EDSS: 2 [0-8]) and 152 healthy controls (91F) were studied. In young patients (<34 years), with low disability (EDSS < 3), the absence of Dawson’s fingers, temporal lobe lesions and longitudinally extensive lesions in the cervical cord pointed towards a diagnosis of MOG-antibody disease instead of the other two diseases (accuracy: 76%, sensitivity: 81%, specificity: 84%, p < 0.001). In these non-acute patients, a number of brain lesions < 6 predicted MOG-antibody disease versus multiple sclerosis (accuracy: 83%, sensitivity: 82%, specificity: 83%, p < 0.001). An EDSS < 3 and the absence of longitudinally extensive lesions in the cervical cord predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, sensitivity: 89%, specificity: 62%, p < 0.001). A workflow with sequential tests and supporting features has been proposed to guide a better identification of MOG-antibody disease patients.
Adult non-acute MOG-antibody disease patients showed distinctive clinical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis. A careful inspection of the morphology of brain and cord lesions together with clinical information, can guide for further analyses towards diagnosis of MOG-antibody disease in clinical practice. | |
dc.language | EN | |
dc.title | Clinical and MRI measures to identify non-acute MOG-antibody disease in adults | |
dc.title.alternative | ENEngelskEnglishClinical and MRI measures to identify non-acute MOG-antibody disease in adults | |
dc.type | Journal article | |
dc.creator.author | Cortese, Rosa | |
dc.creator.author | Battagili, Marco | |
dc.creator.author | Prados, Ferran | |
dc.creator.author | Boanchi, Alessia | |
dc.creator.author | Haider, Lukas | |
dc.creator.author | Jacob, Anu | |
dc.creator.author | Palace, Jacqueline | |
dc.creator.author | Messina, Silvia | |
dc.creator.author | Paul, Friedemann | |
dc.creator.author | Wuerfel, Jens | |
dc.creator.author | Marignier, Romain | |
dc.creator.author | Durand-Dubief, Francoise | |
dc.creator.author | Rimkus, Carolina de Medeiros | |
dc.creator.author | Callegaro, Dagoberto | |
dc.creator.author | Sato, Douglas K | |
dc.creator.author | Filippi, Massimo | |
dc.creator.author | Rocca, Maria A. | |
dc.creator.author | Cacciaguerra, Laura | |
dc.creator.author | Rovira, Alex | |
dc.creator.author | Sastre-Garriga, Jaume | |
dc.creator.author | Arrambide, Georgina | |
dc.creator.author | Liu, Yaou | |
dc.creator.author | Duan, Yunyun | |
dc.creator.author | Gasperini, Claudio | |
dc.creator.author | Tortorella, Carla | |
dc.creator.author | Ruggieri, Serena | |
dc.creator.author | Maria Pia, Amato | |
dc.creator.author | Ulivelli, Monica | |
dc.creator.author | Groppa, Sergiu | |
dc.creator.author | Grothe, Matthias | |
dc.creator.author | Llufriu, Sara | |
dc.creator.author | Sepulveda, Maria | |
dc.creator.author | Lukas, Carsten | |
dc.creator.author | Bellenberg, Barbara | |
dc.creator.author | Schneider, Ruth | |
dc.creator.author | Sowa, Piotr | |
dc.creator.author | Celius, Elisabeth Gulowsen | |
dc.creator.author | Proebstel, Anne-Katrin | |
dc.creator.author | Yaldizli, Özgür | |
dc.creator.author | Müller, Jannis | |
dc.creator.author | Stankoff, B | |
dc.creator.author | Bodini, Benedetta | |
dc.creator.author | Carmisciano, Luca | |
dc.creator.author | Sormani, Maria Pia | |
dc.creator.author | Barkhof, Frederik | |
dc.creator.author | Stefano, Nicola De | |
dc.creator.author | Ciccarelli, Olga | |
cristin.unitcode | 185,53,42,13 | |
cristin.unitname | Nevrologisk avdeling | |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 2116699 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Brain&rft.volume=&rft.spage=&rft.date=2022 | |
dc.identifier.jtitle | Brain | |
dc.identifier.doi | https://doi.org/10.1093/brain/awac480 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0006-8950 | |
dc.type.version | AcceptedVersion | |
cristin.articleid | awac480 | |